Hunting Hill Global Capital, LLC Dynavax Technologies Corp Transaction History

Hunting Hill Global Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 17, 2024	SELL	$10.73 - $12.58 $21,460 - $25,160	-2,000 Reduced 15.38%	11,007 $123,000
Q1 2024 May 15, 2024	BUY	$11.7 - $14.98 $9,746 - $12,478	833 Added 6.84%	13,007 $161,000
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $15,891 - $18,185	-1,214 Reduced 9.07%	12,174 $170,000
Q3 2023 Nov 14, 2023	SELL	$12.64 - $14.99 $12,640 - $14,990	-1,000 Reduced 6.95%	13,388 $197,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.17 $65,010 - $86,922	-6,600 Reduced 31.45%	14,388 $185,000
Q1 2023 May 15, 2023	BUY	$9.44 - $11.88 $47,200 - $59,400	5,000 Added 31.27%	20,988 $205,000
Q4 2022 Feb 14, 2023	SELL	$10.27 - $13.29 $25,675 - $33,225	-2,500 Reduced 13.52%	15,988 $170,000
Q3 2022 Nov 14, 2022	BUY	$9.93 - $17.44 $24,616 - $43,233	2,479 Added 15.49%	18,488 $193,000
Q2 2022 Aug 15, 2022	SELL	$7.45 - $12.83 $2,167 - $3,733	-291 Reduced 1.79%	16,009 $202,000
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $158,925 - $235,372	16,300 New	16,300 $177,000

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.54B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Hunting Hill Global Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Hunting Hill Global Capital, LLC with notifications on news.